Completed NA INTERVENTIONAL NCT00146588

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

A Pilot Study of Cytoxan, Epirubicin, and Capecitabine in Women With Stage I/II/IIIA Breast Cancer

Sponsor: Beth Israel Deaconess Medical Center

Conditions Breast Cancer Stage I Breast Cancer Stage II Breast Cancer Stage IIIA Breast Cancer

Interventions Capecitabine Cyclophosphamide Epirubicin

Updated 6 times since 2017 Last updated: Mar 23, 2015 Started: Apr 30, 2002 Primary completion: Dec 31, 2004 Completion: Dec 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00146588, this NA trial focuses on Breast Cancer and Stage I Breast Cancer and remains completed. Sponsored by Beth Israel Deaconess Medical Center, it has been updated 6 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Feb 2017 — Jun 2018 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Craig A. Bunnell, MD, MPH
Dana-Farber Cancer Institute
Massachusetts General Hospital
Pharmacia

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States